NCT07792954Toboroz3. fázis
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-WEEKLY PF-08653944 IN CHINESE ADULTS WITH OVERWEIGHT OR OBESITY
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. nov. 5.
Rövid összefoglaló (regiszter, angolul)
Overweight and obesity are long-term health conditions that can increase the risk of serious health problems, including heart disease, type 2 diabetes, and other medical conditions. The purpose of this study is to learn whether berobenatide is safe and effective for adults in China who have overweight or obesity. Researchers will compare berobenatide with a placebo, which looks like the study treatment but does not contain active medicine. People may be able to participate if they are adults with obesity or if they have overweight together with certain weight-related health conditions. Some participants may also have type 2 diabetes. Specific eligibility requirements will be reviewed by the study doctor before enrollment. Participants will be randomly assigned to receive either berobenatide or placebo. The study treatment will be administered according to the study protocol, and participants will be monitored throughout the study to assess changes in body weight and overall health, as well as any side effects that may occur. During participation, participants will attend study visits and complete study-related assessments. Researchers will collect information about participants' health, body weight, and safety throughout the study. Details about the number of visits, study duration, and study procedures will be explained by the study team before participation. The information learned from this study may help researchers better understand whether berobenatide could be a treatment option for adults living with overweight or obesity.
- Állapot (regiszter)
- Toboroz
- Fázis (regiszter)
- 3. fázis
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 300 (tervezett)
- Első benyújtás
- 2026. aug. 25.
- Kezdés
- 2026. szept. 24.
- Elsődleges befejezés
- 2028. márc. 14.
- Fő szponzor
- Pfizer
- Betegségek
- Elhízás
- NCT-szám
- NCT07792954
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó · 3. fázis
- Tervezett résztvevők: 300
- 2026. szept. 24. és az elsődleges befejezés (2028. márc. 14.) között
- 34 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- Recent bariatric surgery or obesity procedures.
Más betegség
- Type 1 diabetes mellitus.
- History of pancreatitis.
- Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple endocrine neoplasia type 2 (MEN2).
Egyéb
- Significant recent weight change (>5% within 3 months).
- Pregnancy or breastfeeding.
Kiket keres a vizsgálat
- Adults ≥18 years of age.
- BMI ≥28 kg/m²; or BMI ≥24 kg/m² and <28 kg/m² with at least one weight-related comorbidity.
- Participants with T2D must have HbA1c 6.5% to 10.0%.
- At least one prior unsuccessful dietary weight-loss attempt.
Életkor a regiszterben: 18 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (34)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Beijing Friendship Hospital | Beijing | Kína | Toboroz |
| Beijing Pinggu Hospital | Beijing | Kína | Toboroz |
| Beijing Tsinghua Changgung Hospital | Beijing | Kína | Toboroz |
| Peking University People's Hospital | Beijing | Kína | Toboroz |
| The Second Hospital of Jilin University | Changchun | Kína | Toboroz |
| Changzhou Second People's Hospital | Changzhou | Kína | Toboroz |
| Chongqing People's Hospital | Chongqing | Kína | Toboroz |
| Chongqing University Three Gorges Hospital | Chongqing | Kína | Toboroz |
| Hangzhou First People's Hospital | Hangzhou | Kína | Toborzás még nem indult |
| The Fourth Hospital of Harbin Medical University | Harbin | Kína | Toboroz |
| The Second People's Hospital of Hefei | Hefei | Kína | Toboroz |
| Harrison International Peace Hospital | Hengshui | Kína | Toboroz |
| Huizhou Central People's Hospital | Huizhou | Kína | Toboroz |
| Huzhou Central Hospital | Huzhou | Kína | Toboroz |
| Jinan Central Hospital | Jinan | Kína | Toboroz |
| Luoyang First People's Hospital | Luoyang | Kína | Toboroz |
| The First Affiliated Hospital of Henan University of Science &Technology | Luoyang | Kína | Toboroz |
| Jiangxi Provincial People's Hospital | Nanchang | Kína | Toboroz |
| The Second Affiliated Hospital of Nanjing Medical University | Nanjing | Kína | Toboroz |
| Nanjing First Hospital | Nanjing | Kína | Toboroz |
| Affiliated Hospital of Nantong University | Nantong | Kína | Toboroz |
| The First Affiliated Hospital of Ningbo University | Ningbo | Kína | Toboroz |
| Pingxiang People's Hospital | Pingxiang | Kína | Toboroz |
| Pudong New Area People's Hospital Shanghai | Shanghai | Kína | Toboroz |
| The Fifth People's Hospital of Shanghai | Shanghai | Kína | Toboroz |
| Zhongshan Hospital,Fudan University | Shanghai | Kína | Toboroz |
| Shanghai Tenth People's Hospital | Shanghai | Kína | Toborzás még nem indult |
| The Second Hospital of Hebei Medical University | Shijiazhuang | Kína | Toborzás még nem indult |
| Shiyan Taihe Hospital | Shiyan | Kína | Toborzás még nem indult |
| Tianjin Medical University General Hospital | Tianjin | Kína | Toboroz |
| Wuhan Third Hospital | Wuhan | Kína | Toboroz |
| The First Affiliated Hospital of Xi'an Medical University | Xi'an | Kína | Toboroz |
| The Second Affiliated Hospital of Zhengzhou University | Zhengzhou | Kína | Toboroz |
| Affiliated Hospital of Jiangsu University | Zhenjiang | Kína | Toboroz |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.